CDMOs Rush to Add Syringe Capacity Amid Soaring Demand for Obesity Drugs

Companies are investing billions to expand capacity for filling syringes used for weight-loss drugs like Wegovy and the upcoming Mounjaro.

Demand is soaring for self-injection obesity drugs, with the market potentially worth up to $100 billion in a decade.

WuXi, Catalent, Lonza, Fujifilm and Vetter are among the CDMOs racing to add pre-filled syringe capacity.

Thermo Fisher is converting COVID vaccine capacity for obesity and diabetes drugs amid huge shortages.

Supply constraints likely to persist with projects only completing in 2024-2026, limiting how fast the obesity drug market can grow.